2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 338

The Potent Phosphoinositide-3-Kinase-(δ,γ) Inhibitor IPI-145 Is Active in Preclinical Models of Arthritis and Well Tolerated in Healthy Adult Subjects
Abstract Number: 2071

The Potent, Highly Selective and Orally Bioavailable Spleen Tyrosine Kinase Inhibitor GSK143 Demonstrates Efficacy in B Cell Receptor and Fc Receptor Signalling in Models of Inflammatory and Autoimmune Disease
Abstract Number: 417

The Potential Role of PTPRD Gene Copy Number Variation in Susceptibility to Rheumatoid Arthritis
Abstract Number: 1333

The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4U-study)
Abstract Number: 540

The Predictors of Reduced Work Productivity in Patients with Psoriatic Arthritis
Abstract Number: 69

The Presence of Asymptomatic Carotid Plaques in Patients with Inflammatory Joint Disease Results in Inadequate Treatment to Lipid Targets in Cardiovascular Disease Prevention
Abstract Number: 2493

The Presence of HLA-B27 Shapes Gut Microbiome Composition in Rats
Abstract Number: 532

The Prevalance of Autoimmune Thyroid Disfunction in Ankylosing Spondylitis
Abstract Number: 1036

The Prevalence of Chondrocalcinosis of the Acromioclavicular Joint On Chest Radiographs and correlation with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease
Abstract Number: 164

The Prevalence of Gout in a Large Tertiary Hospital and the Impact of in-Hospital Attacks of Acute Gout On Patient Outcomes and Health Resource Utilisation – a Nested Case-Control Study
Abstract Number: 2354

The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment?
Abstract Number: 273

The Prevalence of Periarticular Lesions On Magnetic Resonance Imaging and Its Relation to Knee Pain in the Community Residents in Korea
Abstract Number: 1354

The Prevalence of Psoriatic Arthritis Based On Rheumatologists’ Clinical Assessment Before and After Laboratory and Radiographic Tests in Psoriasis Patients in European/North American Dermatology Clinics
Abstract Number: 1049

The Prevalence of the Ultrasonographic Positive Power Doppler Synovitis Is High and Predicts the Risk of Relapse and Structural Progression in Rheumatoid Arthritis in Clinical Remission: A Systematic Literature Review and Meta Analysis
Abstract Number: 1805

The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].